ERBB2 and gastric cancer: Furthermore, zolbetuximab has recently been shown to be effective against HER2-negative, Claudin (CLDN)-positive gastric cancer [44,45], and further discussion is needed regarding treatment strategies for HER2-negative, CLDN-positive gastric cancer with low PD-L1 expression.